Drug intelligence / Profile preview

SY-3

Development stage: Preclinical
Lead developer: Samyoung Unitech
Modality: Peptides

Overview

**SY-3** is a preclinical **EPO-derived peptide** candidate from **Samyoung Unitech** for **acute ischemic stroke**. It is described as acting on the **erythropoietin receptor** with **neuroprotective EPOR agonist** activity, and appears to be part of a peptide platform associated with **Sylus Bio Therapeutics**, the Samyoung Unitech and DGIST joint venture. Available pipeline context indicates that mechanism and efficacy have been confirmed in preclinical work and that the program is in candidate-selection stage with nonclinical preparation underway for cerebral infarction.

Other names: EPOR peptide

Targets

Erythropoietin Receptor

Beyond the preview

Go deeper on SY-3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SY-3.

Explore the full profile